NCT07321028
Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)
Enrolling by Invitation
EARLY_PHASE1All AgesInterventionalTreatmentTruway Health, Inc.
~50 participants
Updated 2026-01-06 on ClinicalTrials.gov
What's tested:Standard Laboratory Cryopreservation ProcedureEnhanced Laboratory Cryopreservation ProcedureNormothermic Cell Culture Control
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Post-Thaw Viability
Measured over Twenty-four (24) hours after thaw
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Gavin Solomon, President & CEO · PRINCIPAL_INVESTIGATOR · Truway Health, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
This study does not enroll human participants. Eligibility applies only to human-derived cell samples.
Samples must be de-identified prior to receipt.
Samples must demonstrate ≥90% viability at pre-freeze assessment.
Samples must be free of contamination (bacterial, fungal, mycoplasma).
Samples must meet chain-of-custody and biospecimen compliance requirements.
Exclusion
No human participants will be enrolled or contacted.
Any specimen containing identifiable private information.
Samples with inadequate quality, contamination, or compromised viability.
Samples obtained without appropriate donor consent or de-identification certification.
What this trial measures
- Post-Thaw ViabilityTwenty-four (24) hours after thaw
Percentage of viable cells determined by trypan blue exclusion assay or automated cell viability analyzer.